葡萄糖依赖型胰岛素 (GIP) 在PCOS小鼠模型和细胞系统中抑制了雄激素生物合成
Mengru Pan1,2, Yifan Qian1, Linlin Jiang1
1Reproductive Medical Center, Department of Obstetrics and Gynecology, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
概括
葡萄糖依赖胰岛素 (GIP) 在多囊性卵巢综合征 (PCOS) 模型中有效降低了雄激素合成. 这一发现突出了GIP作为管理PCOS及其相关超原体的潜在治疗点.
科学领域:
- 内分泌学 在内分泌学.
- 生殖生物学 生殖生物学
- 分子生物学分子生物学
背景情况:
- 过高雄性是多囊性卵巢综合征 (PCOS) 的一个关键特征.
- 目前用于治疗PCOS症状的治疗方法,如高雄性质症,具有局限性.
- 葡萄糖依赖性胰岛素 (GIP) 是一种具有潜在代谢作用的隐形激素.
研究的目的:
- 调查GIP在治疗PCOS相关的过高雄激素的治疗潜力.
- 阐明GIP影响雄激素合成的分子机制.
主要方法:
- 已确立的脱氨 (DHEA) 诱导的PCOS小鼠模型用于体内研究.
- 使用NCI-H295R细胞进行体外研究,研究GIP对雄激素合成的影响.
- 采用CCK8,流细胞测量,RT-qPCR,西斑,ELISA和RNA测序 (RNA-seq) 进行细胞分析.
主要成果:
- 在DHEA诱导的PCOS小鼠模型中,GIP的使用显著降低了丸激素水平.
- 在体外,GIP治疗降低了NCI-H295R细胞中的激素分泌量,并降低了NCI-H295R细胞中的关键类固醇基因 (GIPR,STAR,CYP11A1,CYP17A1).
- RNA-seq发现PSENEN是一种由GIP显著下调的基因;PSENEN敲击进一步降低了丸激素,证实了它在GIP抑制作用中的作用.
结论:
- 在体内和体外,GIP对雄激素合成具有显著的抑制作用.
- GIP作为PCOS的新型治疗剂具有前景,特别是用于管理高雄性质症.
- 针对GIP信号可能为PCOS治疗提供新的策略.
相关概念视频
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
Cell Specific Gene Expression
16.2K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.2K
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566


